Discovery Toxicology at CBI

Discovery toxicology is a key process in the identification, characterization and selection of new drug therapies for development. CBI offers a number of fast, cost-effective research programs designed to assess, characterize and rank new therapies for toxicity and efficacy and to assist in the selection process.

For early discovery toxicology projects, CBI also offers a range of non-GLP exploratory toxicity studies for early assessment of therapies including single dose, multiple dose and targeted studies, as well as directed or investigative toxicology.

CBI offers a robust and efficient toxicology program to support your preclinical needs. CBI can take you from discovery toxicology all the way to regulatory submission for your therapy. CBI has the capabilities to support both in vivo evaluation and histopathological analysis of your compound in house. All of our slides are read by a board certified veterinary pathologist. All of our GLP reports are made ready for regulatory submission. Contact Us!


  • Standard routes
  • Intravesicular
  • Intravaginal
  • Intrarectal
  • Intranasal
  • Intradermal
  • Ocular
  • Aural-otic
  • Buccal
  • Patches
  • Devices
  • Device-drug combination
  • Infusion
  • Dermal
  • Topical
  • Wounds
  • Sublingual
  • Nanoparticles
  • Device stem cell combination
  • Intrathecal
  • Intracerebral
  • Intratumoral
  • Intracardiac
  • Intra-intestinal
  • Others upon request


Acute Studies

  • Acute
  • Dose ranging
  • Limit dosing
  • Maximum tolerated dose
  • Single dose

Subacute & Subchronic

  • 1-week subacute
  • 2-week subacute
  • 4-week subchronic
  • 8-week subchronic

Chronic & Carcinogenicity

  • 3-month chronic
  • 6-month chronic
  • 9-month chronic
  • 1-year carcinogenicity
  • 2-year carcinogenicity

Special or custom toxicology

  • 1-year chronic
  • 2-year chronic
  • Stem cells implantation
  • Surgical toxicity
  • Transgenic carcinogenicity
  • Others upon request